Comparison 21. Minocycline 100 mg od maintenance.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Lesion count ‐ percentage change from baseline versus tazarotene	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
1.1 NIL	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 IL	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Overall disease severity score versus tazarotene	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3 Overall clinical improvement ‐ Dr‐assessed versus tazarotene	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 < = 50%	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 > = 75%	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Lesion count ‐ percentage change from baseline versus tazarotene/minocycline combination	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 IL	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 NIL	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Overall disease severity score versus tazarotene/minocycline combination	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6 Overall clinical improvement ‐ Dr‐assessed versus tazarotene/minocycline combination	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6.1 < = 50%	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 > = 75%	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]